Myelofibrosis Clinical Trials
Myelofibrosis clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for myelofibrosis. Corterve aggregates actively recruiting Myelofibrosis studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Myelofibrosis studies
- A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)NCT07357727PHASE3Novartis PharmaceuticalsPrimary Myelofibrosis (PMF)New Haven, Connecticut
- Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesNCT06398457EARLY_PHASE1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsHematologic MalignancyBaltimore, Maryland
- A Study of Oral Nuvisertib (TP-3654) in Patients With MyelofibrosisNCT04176198PHASE1, PHASE2Sumitomo Pharma America, Inc.MyelofibrosisBirmingham, Alabama
- A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking RuxolitinibNCT07623161PHASE3TakedaMyelofibrosisGilbert, Arizona
- A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsNCT07469891PHASE1Prelude Therapeutics IncorporatedPolycythemia Vera (PV)Los Angeles, California
- Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in MyelofibrosisNCT07521046PHASE1University of UtahMyelofibrosisSalt Lake City, Utah
- A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)NCT06661915PHASE2National Cancer Institute (NCI)Accelerated Phase Myeloproliferative NeoplasmIrvine, California
- Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and AnemiaNCT05320198PHASE1, PHASE2Disc Medicine, IncMyelofibrosis; AnemiaGilbert, Arizona
- Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsNCT04282187PHASE2University of WashingtonAcute Myeloid LeukemiaSeattle, Washington
- A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)NCT06343805PHASE1Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyPrimary MyelofibrosisPalo Alto, California
- High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With SplenomegalyNCT06345495PHASE2M.D. Anderson Cancer CenterSplenomegalyHouston, Texas
- Pacritinib Effectiveness in Real-world SettingsNCT07774455Swedish Orphan BiovitrumMyelofibrosis (MF)New Haven, Connecticut
Myelofibrosis trials by state
Myelofibrosis trials by metro
Frequently asked questions
- How do I find recruiting Myelofibrosis clinical trials?
- Browse the actively recruiting Myelofibrosis studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.
- Are Myelofibrosis clinical trials free to join?
- Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.
- Who can take part in a Myelofibrosis clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.